Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 3Phase 1/2 2Phase 1 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 91Melanoma 74Squamous Cell Carcinoma of Head and Neck 47Neoplasms 44Neoplasm Metastasis 43Lung Neoplasms 37Carcinoma, Renal Cell 36Colorectal Neoplasms 35Breast Neoplasms 34Triple Negative Breast Neoplasms 30Stomach Neoplasms 26Carcinoma, Transitional Cell 26Ovarian Neoplasms 25Head and Neck Neoplasms 24Parkinson Disease 4, Autosomal Dominant Lewy Body 21Esophageal Neoplasms 20Pancreatic Neoplasms 18Uterine Cervical Neoplasms 17Urinary Bladder Neoplasms 16Endometrial Neoplasms 16Small Cell Lung Carcinoma 15Carcinoma, Hepatocellular 15Sarcoma 13Recurrence 12Glioblastoma 12Carcinoma 12Prostatic Neoplasms 11Lymphoma 11Mesothelioma 9Carcinoma, Merkel Cell 9

Interventions

Gemcitabine 4Oxaliplatin 3pembrolizumab 2tivozanib 1peposertib 1fludarabine 1durvalumab 1devimistat 1avelumab 1atezolizumab 1aldesleukin 1Temozolomide 1Specimen Handling 1Sorafenib 1Radiotherapy 1Radiation Dose Hypofractionation 1Radiation 1Pemetrexed 1Leucovorin 1Irinotecan 1Interleukin-2 1Fluorouracil 1Cyclophosphamide 1Cisplatin 1Capecitabine 1Cannabidiol 1Bortezomib 1Biopsy 1Bevacizumab 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Gallbladder Neoplasms × pembrolizumab × Clear all
NCT04585750 2026-03-12

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

PMV Pharmaceuticals, Inc

Phase 1/2 Recruiting
300 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gallbladder Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT07269158 2025-12-08

A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer

Yonsei University

Phase 1/2 Not yet recruiting
160 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡